Substituted Imidazole Derivatives and Methods of Use Thereof

Abstract

The present invention provides imidazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof. and their use in the treatment of diseases.

We claim: 
     
         1 . A method for treating a disease or condition comprising administering to a subject a compound of Formula (I) or a pharmaceutically acceptable salt thereof, 
       
         
           
           
               
               
           
         
       
       wherein
 R 1  and R 2  are independently selected from the group consisting of: —CH 3 , —CH 2 CH 3 , —CH(CH 3 ) 2 , and —CH 2 CH 2 CH 3 ; and — 
 Q 1  is selected from the group consisting of —CH 2 OCH 2 CH 3  and —CH 2 CH 2 CH 2 CH 3 ; and 
 
       wherein 
       the disease or condition is selected from the group consisting of: acute inflammation, chronic inflammation, skin inflammation, psoriasis, atopic dermatitis, inflammation associated with organ, tissue, or cell transplantation, lung inflammation, asthma, chronic osbtructive pulmonary disease, sepsis, diabetes, renal failure, hyperlipidemic atherosclerosis associated with diabetes, restenosis, Down's syndrome, dementia associated with head trauma, amyotrophic lateral sclerosis, multiple sclerosis, amyloidosis, an autoimmune disease, impaired wound healing, periodontal disease, neuropathy, neuronal degeneration, vascular permeability, nephropathy, atherosclerosis, retinopathy, erectile dysfunction, and osteoporosis. 
     
     
         2 . The method of  claim 1 , wherein the compound is (R)-1-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-3-dimethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The method of  claim 1 , wherein the compound is (R)-1-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-3-diethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         4 . The method of  claim 1 , wherein the compound is (S)-1-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-3-dimethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The method of  claim 1 , wherein the compound is (S)-1-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-3-diethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 1 , wherein the compound is (R)-1-(4-{1-[4-(4-chloro-phenoxy)-phenyl]-2-ethoxymethyl-1H-imidazol-4-yl}-phenoxy)-3-dimethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         7 . The method of  claim 1 , wherein the compound is (S)-1-(4-{1-[4-(4-chloro-phenoxy)-phenyl]-2-ethoxymethyl-1H-imidazol-4-yl}-phenoxy)-3-dimethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         8 . The method of  claim 1 , wherein the compound is (R)-1-(4-{1-[4-(4-chloro-phenoxy)-phenyl]-2-ethoxymethyl-1H-imidazol-4-yl}-phenoxy)-3-diethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method of  claim 1 , wherein the compound is (S)-1-(4-{1-[4-(4-chloro-phenoxy)-phenyl]-2-ethoxymethyl-1H-imidazol-4-yl}-phenoxy)-3-diethylamino-propan-2-ol or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The method of  claim 1 , wherein the disease or condition is sepsis. 
     
     
         11 . The method of  claim 1 , wherein the disease or condition is diabetes. 
     
     
         12 . The method of  claim 1 , wherein the disease or condition is asthma. 
     
     
         13 . The method of  claim 1 , wherein the disease or condition is nephropathy. 
     
     
         14 . The method of  claim 1 , wherein the disease or condition is chronic osbtructive pulmonary disease.